Association between acromegaly and a single nucleotide polymorphism (rs543019827, rs547640100, rs545558970, rs2453837, and rs6953668 A/G) in the IGFBP3 gene in Iraqi Acromegaly Diabetic Patients
Main Article Content
Keywords
Acromegaly, IGFBP-3 gene, rs543019827C/T, rs547640100C/T, rs545558970A/G, rs2453837 C/T, and rs6953668 A/G
Abstract
Objective: This study aimed Study the genetic polymorphism of the IGFBP-3 gene that is responsible for the synthesis of IGFBP3 protein and its association with acromegaly patients.
Methods: This study was done at the National Diabetes center/Mustansiriyah University between October 2021 and the end of April 2022. Nighty participate in this study (50) acromegaly diabetic patients and (40) healthy control compared patients. In this study, Genomic DNA was extracted then genotyping was performed to detect the single nucleotide polymorphisms (SNPs) in the IGFBP-3 gene using a specific primer.
Results: This is the first study to give frequency distribution genotypes of the IGFBP-3 gene in patients with active acromegaly in Iraq, The IGFBP-3 gene promoter selected region consists of 440 bp, which is highly suspected as a transcription factor binding site (TFBS), and was subjected to DNA sequencing to detect SNPs (point mutations) that might affect to cause disease. These sequences were scanned in 20 individuals, 15 of whom were acromegaly patients and 5 of whom were controls, only five SNPs in the IGFBP-3 gene were selected (rs543019827C/T, rs547640100C/T, rs545558970A/G, rs2453837 C/T, and rs6953668 A/G). The sequence data of 20 samples demonstrated that (rs543019827 C/T, rs545558970 A/G, and rs6953668 A/G) SNPs in the IGFBP-3 gene showed significantly different frequencies of heterozygous genotype (P-value <0.05).
Conclusion: In (rs543019827 C/T) SNP the odds ratio for the CT genotype was 16, in (rs545558970 A/G) SNP the odds ratio for the AG genotype was 4.13, and in (rs6953668 A/G) SNP the odds ratio for the AG genotype was 1.83, this means that person who caring these genotypes have a higher risk for disease than other genotypes.
References
2. Bembi, R. (2020). Oro-Dental Manifestations in Patients with Acromegaly: A Case Report. EC Dental Science, 19, 99–106.
3. Bonilla, C., Lewis, S. J., Rowlands, M., Gaunt, T. R., Davey Smith, G., Gunnell, D., Palmer, T., Donovan, J. L., Hamdy, F. C., & Neal, D. E. (2016). Assessing the role of insulin‐like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. International Journal of Cancer, 139(7), 1520–1533.
4. Cai, Q., Dozmorov, M., & Oh, Y. (2020). IGFBP-3/IGFBP-3 Receptor System as an Anti-Tumor and Anti-Metastatic Signaling in Cancer. Cells, 9(5). https://doi.org/10.3390/cells9051261
5. Caputo, M., Pigni, S., Agosti, E., Daffara, T., Ferrero, A., Filigheddu, N., & Prodam, F. (2021). Regulation of GH and GH Signaling by Nutrients. Cells, 10(6), 1376.
6. Daly, A. F., Rostomyan, L., Betea, D., Bonneville, J.-F., Villa, C., Pellegata, N. S., Waser, B., Reubi, J.-C., Stephan, C. W., & Christ, E. (2019). AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. Endocrine Connections, 8(4), 367–377.
7. Gao, M., Zhu, B., Xu, Z., Liu, S., Liu, J., Zhang, G., Gao, Y., Fan, Y., & Kang, X. (2018). Association between acromegaly and a single nucleotide polymorphism (rs2854744) in the IGFBP3 gene. BMC Medical Genetics, 19(1), 1–7.
8. Garcia de la Serrana, D., & Macqueen, D. J. (2018). Insulin-like growth factor-binding proteins of teleost fishes. Frontiers in Endocrinology, 9, 80.
9. Kasuki, L., Antunes, X., Lamback, E. B., & Gadelha, M. R. (2020). Acromegaly: update on management and long-term morbidities. Endocrinology and Metabolism Clinics, 49(3), 475–486.
10. Liu, C., Tang, W., Chen, S., Wang, Y., Qiu, H., Yin, J., & Gu, H. (2015). IGFBP3 polymorphisms and risk of esophageal cancer in a Chinese population. International Journal of Clinical and Experimental Medicine, 8(9), 17006–17014.
11. Murphy, N., Carreras-Torres, R., Song, M., Chan, A. T., Martin, R. M., Papadimitriou, N., Dimou, N., Tsilidis, K. K., Banbury, B., & Bradbury, K. E. (2020). Circulating levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 associate with risk of colorectal cancer based on serologic and Mendelian randomization analyses. Gastroenterology, 158(5), 1300–1312.
12. Qin, Z., Li, X., Tang, J., Jiang, X., Yu, Y., Wang, C., Xu, W., Hua, Y., Yu, B., & Zhang, W. (2016). Association between insulin-like growth factor-binding protein-3 polymorphism-202 A/C and the risk of prostate cancer: a meta-analysis. OncoTargets and Therapy, 9, 5451.
13. Ramos-Leví, A. M., Marazuela, M., Paniagua, A., Quinteiro, C., Riveiro, J., Álvarez-Escolá, C., Lucas, T., Blanco, C., De Miguel, P., De Icaya, P. M., Pavón, I., & Bernabeu, I. (2015). Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: Association with clinical presentation and response to treatments. European Journal of Endocrinology, 172(2), 115–122. https://doi.org/10.1530/EJE-14-0613
14. Ren, Z., Cai, Q., Shu, X. O., Cai, H., Li, C., Yu, H., Gao, Y. T., & Zheng, W. (2004). Genetic polymorphisms in the IGFBP3 gene: Association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiology Biomarkers and Prevention, 13(8), 1290–1295. https://doi.org/10.1158/1055-9965.1290.13.8
15. Rodriguez, S., Gaunt, T. R., & Day, I. N. M. (2009). Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. American Journal of Epidemiology, 169(4), 505–514.
16. Stiles, C. E., Hossain, B., & Drake, W. M. (2021). Acromegaly. Medicine, 49(8), 488–491.
17. Tang, W., Chen, S., Liu, J., Liu, C., Wang, Y., & Kang, M. (2019). Investigation of IGF1, IGF2BP2, and IGFBP3 variants with lymph node status and esophagogastric junction adenocarcinoma risk. Journal of Cellular Biochemistry, 120(4), 5510–5518. https://doi.org/10.1002/jcb.27834